{"id":"NCT03538691","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-13","primaryCompletion":"2022-07-08","completion":"2022-07-29","firstPosted":"2018-05-29","resultsPosted":"2023-10-12","lastUpdate":"2023-10-12"},"enrollment":1149,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":["OPC-34712","Rexulti"]},{"type":"DRUG","name":"Antidepressant therapy","otherNames":[]}],"arms":[{"label":"Phase A: Brexpiprazole + ADT","type":"EXPERIMENTAL"},{"label":"Phase B: Brexpiprazole + ADT","type":"EXPERIMENTAL"},{"label":"Phase C: Brexpiprazole + ADT","type":"EXPERIMENTAL"},{"label":"Phase C: Placebo + ADT","type":"EXPERIMENTAL"}],"summary":"Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging.\n\nThis study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.","primaryOutcome":{"measure":"Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum","timeFrame":"Up to 14 days post last dose in Phase C (up to 28 weeks)","effectByArm":[{"arm":"Phase C: Brexpiprazole + ADT","deltaMin":63,"sd":null},{"arm":"Phase C: Placebo + ADT","deltaMin":63,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5100"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":29},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["39415650"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":1136},"commonTop":["Weight increased","Headache","Akathisia","Somnolence","Insomnia"]}}